Department of Clinical Pathology, Haematology Unit, Mansoura University Oncology Centre, Mansoura University, Egypt.
Mansoura University Oncology Center Laboratories; Mansoura University; Egypt.
Asian Pac J Cancer Prev. 2021 Jun 1;22(6):1821-1826. doi: 10.31557/APJCP.2021.22.6.1821.
Recent reports suggested relation between Interferon Gamma (IFN-γ) gene polymorphism and the risk of development of HCC on top of hepatic cirrhosis. The aim of this study was to address the predictive value of Interferon Gamma gene receptor (IFN-γR) polymorphisms for the occurrence of hepatocellular carcinoma on top of liver cirrhosis.
This is a case control study performed on patients selected from the outpatient hepatology clinic, specialized medical hospital, Mansoura University, Egypt, from August 2017 to February 2019. The included patients were categorized into two groups; 60 patients with HCC on top of cirrhosis and 20 patients with hepatic cirrhosis. For all patients IFN-γR polymorphism was identified by RFLP.
Our study showed that HCC patients had male predominance. Additionally, diabetes mellitus (DM) was found in 28.3% of total HCC patients. Half of HCC patients in this study were from rural areas (50%). The frequency of AA at position -611 in the IFN-γR (-611 IFN-γR) was significantly higher in the HCC group as compared to cirrhotic group (P=0.021). Moreover; the frequency of CC and CT genotypes of IFN-γR -56 was not significantly different in HCC group as compared to control group (P>0.05). The IFN-γR (-611 IFN-γ) AA genotype significantly increased risk of HCC (OR= 0.78, 95% CI= 0.10-6.39; P= 0.042).
The analysis of IFN-γR -611 single nucleotide gene polymorphism could be a valuable marker for predicting subgroup of cirrhotic patients with high risk of developing HCC. Cirrhotic patients have AA genotype of IFN-γR-611 recommended to be under close follow up.
最近的报告表明,干扰素γ(IFN-γ)基因多态性与肝硬化基础上 HCC 的发展风险之间存在关联。本研究旨在探讨干扰素γ受体(IFN-γR)多态性对肝硬化基础上发生肝细胞癌(HCC)的预测价值。
这是一项病例对照研究,于 2017 年 8 月至 2019 年 2 月在埃及曼苏拉大学专门医疗医院的门诊肝病诊所对患者进行。纳入的患者分为两组;60 例肝硬化合并 HCC 患者和 20 例肝硬化患者。对所有患者的 IFN-γR 多态性进行了 RFLP 鉴定。
本研究显示,HCC 患者以男性为主。此外,在所有 HCC 患者中,糖尿病(DM)的发生率为 28.3%。本研究中一半的 HCC 患者来自农村地区(50%)。IFN-γR(-611 IFN-γR)的位置-611 处 AA 的频率在 HCC 组明显高于肝硬化组(P=0.021)。此外,HCC 组与对照组 IFN-γR-56 的 CC 和 CT 基因型频率无显著差异(P>0.05)。IFN-γR(-611 IFN-γ)AA 基因型显著增加 HCC 发病风险(OR=0.78,95%CI=0.10-6.39;P=0.042)。
IFN-γR-611 单核苷酸基因多态性分析可能是预测肝硬化患者中发生 HCC 风险较高亚组的有价值标志物。建议对具有 IFN-γR-611AA 基因型的肝硬化患者进行密切随访。